Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial

Smith Corey; Beagley Leone; Rehan Sweera; Neller Michelle A.; Crooks Pauline; Solomon Matthew; Holmes-Liew Chien-Li; Holmes Mark; McKenzie Scott C.; Hopkins Peter; Campbell Scott; Francis Ross S.; Chambers Daniel C.; Khanna Rajiv

首页> 外文期刊>Clinical infectious diseases >Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial

【24h】

Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial

机译：固体器官移植受体中的复发或耐药性患有毒性细胞病毒并发症的自体养老细胞治疗：单臂开放标签I临床试验

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background. Opportunistic infections including cytomegalovirus (CMV) are a major cause of morbidity and mortality in solid organ transplant (SOT) recipients. The recurrent and protracted use of antiviral drugs with eventual emergence of drug resistance represents a significant constraint to therapy. Although adoptive T-cell therapy has been successfully used in hematopoietic stem cell transplant recipients, its extension to the SOT setting poses a considerable challenge because of the inhibitory effects of immunosuppressive drugs on the virus-specific T-cell response in vivo and the perceived risk of graft rejection.

机译：背景。包括巨细胞病毒（CMV）在内的机会性感染是固体器官移植（SOT）受者的发病率和死亡率的主要原因。抗病毒药物具有最终出现的耐药性的反复性和伸长的使用代表了对疗法的重大限制。虽然采用T细胞治疗已成功用于造血干细胞移植受体，但由于免疫抑制药物对体内病毒特异性T细胞反应的抑制作用和感知风险，其对SOT设置的延伸构成了相当大的挑战移植物抑制。

著录项

来源
《Clinical infectious diseases》 |2019年第4期|共9页
作者
Smith Corey; Beagley Leone; Rehan Sweera; Neller Michelle A.; Crooks Pauline; Solomon Matthew; Holmes-Liew Chien-Li; Holmes Mark; McKenzie Scott C.; Hopkins Peter; Campbell Scott; Francis Ross S.; Chambers Daniel C.; Khanna Rajiv;
展开▼
作者单位

QIMR Berghofer Med Res Inst QIMR Ctr Immunotherapy &

Vaccine Dev Brisbane Qld Australia;

QIMR Berghofer Med Res Inst QIMR Ctr Immunotherapy &

Vaccine Dev Brisbane Qld Australia;

QIMR Berghofer Med Res Inst QIMR Ctr Immunotherapy &

Vaccine Dev Brisbane Qld Australia;

QIMR Berghofer Med Res Inst QIMR Ctr Immunotherapy &

Vaccine Dev Brisbane Qld Australia;

QIMR Berghofer Med Res Inst QIMR Ctr Immunotherapy &

Vaccine Dev Brisbane Qld Australia;

QIMR Berghofer Med Res Inst QIMR Ctr Immunotherapy &

Vaccine Dev Brisbane Qld Australia;

Royal Adelaide Hosp Dept Thorac Med South Australian Lung Transplant Unit Adelaide SA Australia;

Royal Adelaide Hosp Dept Thorac Med South Australian Lung Transplant Unit Adelaide SA Australia;

Prince Charles Hosp Adv Heart Failure &

Cardiac Transplant Unit Brisbane Qld Australia;

Prince Charles Hosp Queenland Lung Transplant Serv Brisbane Qld Australia;

Princess Alexandra Hosp Dept Nephrol Brisbane Qld Australia;

Princess Alexandra Hosp Dept Nephrol Brisbane Qld Australia;

Prince Charles Hosp Queenland Lung Transplant Serv Brisbane Qld Australia;

QIMR Berghofer Med Res Inst QIMR Ctr Immunotherapy &

Vaccine Dev Brisbane Qld Australia;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类传染病;
关键词
immunotherapy; T cells; virus infection; transplant; cytomegalovirus;

机译：免疫疗法;T细胞;病毒感染;移植;塞细胞病毒;

相似文献

外文文献
中文文献
专利

1. Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial [J] . Smith Corey, Beagley Leone, Rehan Sweera, Clinical infectious diseases . 2019,第4期

机译：固体器官移植受体中的复发或耐药性患有毒性细胞病毒并发症的自体养老细胞治疗：单臂开放标签I临床试验
2. Generation of HCMV-specific T-cell lines from seropositive solid-organ-transplant recipients for adoptive T-cell therapy. [J] . Journal of immunotherapy . 2009,第9期

机译：从血清阳性实体器官移植接受者生成HCMV特异性T细胞系，用于过继T细胞治疗。
3. Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study [J] . Kazuhiro Kakimi, Hirokazu Matsushita, Keita Masuzawa, Journal for ImmunoTherapy of Cancer . 2020,第2期

机译：在治疗 - 难治性非小细胞肺癌患者中采用唑酮膨胀的自体Vγ9Vδ2T细胞：多中心，开放标签，单臂，第2期研究
4. Phase 1 Trial of Retroviral-Mediated Transfer of the Human MDR-1 In Patients Undergoing High-Dose Chemotherapy and Autologous Stem Cell Transplantation [C] . Charles Hesdorffer, Janet Ayello, Maureen Ward, Keio International Symposium for Life Sciences and Medicine . 2000

机译：逆转录病毒介导的人MDR-1转移的第1期试验在接受高剂量化疗和自体干细胞移植的患者中
5. The Clinical and Economic Burden of Infections in Hospitalized Solid Organ Transplant Recipients in Canada [D] . Hamandi, Bassem. 2020

机译：加拿大住院固体器官移植受者感染的临床和经济负担
6. Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter open-label single-arm phase 2 study [O] . Kazuhiro Kakimi, Hirokazu Matsushita, Keita Masuzawa, 2020

机译：在治疗 - 难治性非小细胞肺癌患者中采用唑酮膨胀的自体Vγ9Vδ2T细胞：多中心开放标签单臂第2期研究
7. Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial [O] . Corey Smith, Leone Beagley, Sweera Rehan, 2018

机译：固体器官移植受者的复发或耐药性患有抗药性患者的自体养殖T细胞疗法：单臂开放标签I临床试验

Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial

摘要

著录项

相似文献

相关主题

期刊订阅